The company's inhaled halothane was approved for sale in the U.S. and four products including iodixanol obtained the EU drug GMP certificate
Recently, Hengrui Medicine received a notification from the US Food and Drug Administration (FDA) that halothane for inhalation was approved for sale in the United States. The original desflurane trade name is Suprane, which is suitable for maintaining anesthesia for inpatient and outpatient adult, infant, and child surgery patients. In the first three quarters of 2017, the global market sales of desflurane were about US $ 200 million. Currently, in addition to the original research company Baxter in the United States and China, desflurane generic drugs have been approved for listing.